Literature DB >> 28446063

Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities.

Kole T Roybal1, Wendell A Lim2.   

Abstract

The ability of immune cells to survey tissues and sense pathologic insults and deviations makes them a unique platform for interfacing with the body and disease. With the rapid advancement of synthetic biology, we can now engineer and equip immune cells with new sensors and controllable therapeutic response programs to sense and treat diseases that our natural immune system cannot normally handle. Here we review the current state of engineered immune cell therapeutics and their unique capabilities compared to small molecules and biologics. We then discuss how engineered immune cells are being designed to combat cancer, focusing on how new synthetic biology tools are providing potential ways to overcome the major roadblocks for treatment. Finally, we give a long-term vision for the use of synthetic biology to engineer immune cells as a general sensor-response platform to precisely detect disease, to remodel disease microenvironments, and to treat a potentially wide range of challenging diseases.

Entities:  

Keywords:  T cells; chimeric antigen receptors; engineered immune cells; immunotherapy; synthetic Notch; synthetic biology

Mesh:

Substances:

Year:  2017        PMID: 28446063      PMCID: PMC5555230          DOI: 10.1146/annurev-immunol-051116-052302

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  116 in total

1.  Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.

Authors:  Ling Zhang; Sid P Kerkar; Zhiya Yu; Zhili Zheng; Shicheng Yang; Nicholas P Restifo; Steven A Rosenberg; Richard A Morgan
Journal:  Mol Ther       Date:  2011-02-01       Impact factor: 11.454

Review 2.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

3.  Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes.

Authors:  Yozo Nakazawa; Leslie E Huye; Gianpietro Dotti; Aaron E Foster; Juan F Vera; Pallavi R Manuri; Carl H June; Cliona M Rooney; Matthew H Wilson
Journal:  J Immunother       Date:  2009-10       Impact factor: 4.456

4.  Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.

Authors:  Evripidis Lanitis; Mathilde Poussin; Alex W Klattenhoff; Degang Song; Raphael Sandaltzopoulos; Carl H June; Daniel J Powell
Journal:  Cancer Immunol Res       Date:  2013-07       Impact factor: 11.151

Review 5.  Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors:  Padmanee Sharma; James P Allison
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

6.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

Authors:  Hollie J Pegram; James C Lee; Erik G Hayman; Gavin H Imperato; Thomas F Tedder; Michel Sadelain; Renier J Brentjens
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

7.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

8.  Prospects for gene-engineered T cell immunotherapy for solid cancers.

Authors:  Christopher A Klebanoff; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Med       Date:  2016-01       Impact factor: 53.440

9.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

10.  Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors.

Authors:  Leonardo Morsut; Kole T Roybal; Xin Xiong; Russell M Gordley; Scott M Coyle; Matthew Thomson; Wendell A Lim
Journal:  Cell       Date:  2016-01-28       Impact factor: 41.582

View more
  39 in total

1.  Engineering multicellular systems: using synthetic biology to control tissue self-organization.

Authors:  Marion B Johnson; Alexander R March; Leonardo Morsut
Journal:  Curr Opin Biomed Eng       Date:  2017-12

2.  A Deep Neural Network for Predicting and Engineering Alternative Polyadenylation.

Authors:  Nicholas Bogard; Johannes Linder; Alexander B Rosenberg; Georg Seelig
Journal:  Cell       Date:  2019-06-06       Impact factor: 41.582

Review 3.  Nucleic Acid-Based Therapeutics Relevant to Neuroimmune Conditions.

Authors:  Ariele L Greenfield; Stephen L Hauser
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

Review 4.  Synthetic Switches and Regulatory Circuits in Plants.

Authors:  Jennifer Andres; Tim Blomeier; Matias D Zurbriggen
Journal:  Plant Physiol       Date:  2019-01-28       Impact factor: 8.340

5.  Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40.

Authors:  Aaron E Foster; Aruna Mahendravada; Nicholas P Shinners; Wei-Chun Chang; Jeannette Crisostomo; An Lu; Mariam Khalil; Eva Morschl; Joanne L Shaw; Sunandan Saha; MyLinh T Duong; Matthew R Collinson-Pautz; David L Torres; Tania Rodriguez; Tsvetelina Pentcheva-Hoang; J Henri Bayle; Kevin M Slawin; David M Spencer
Journal:  Mol Ther       Date:  2017-07-08       Impact factor: 11.454

6.  B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.

Authors:  Yu-Tzu Tai; Kenneth C Anderson
Journal:  Expert Opin Biol Ther       Date:  2019-07-11       Impact factor: 4.388

7.  High-throughput antibody engineering in mammalian cells by CRISPR/Cas9-mediated homology-directed mutagenesis.

Authors:  Derek M Mason; Cédric R Weber; Cristina Parola; Simon M Meng; Victor Greiff; William J Kelton; Sai T Reddy
Journal:  Nucleic Acids Res       Date:  2018-08-21       Impact factor: 16.971

8.  Multiscale engineering of immune cells and lymphoid organs.

Authors:  Sungwoong Kim; Shivem B Shah; Pamela L Graney; Ankur Singh
Journal:  Nat Rev Mater       Date:  2019-04-03       Impact factor: 66.308

Review 9.  Newly identified T cell subsets in mechanistic studies of food immunotherapy.

Authors:  Vanitha Sampath; Kari C Nadeau
Journal:  J Clin Invest       Date:  2019-04-01       Impact factor: 14.808

Review 10.  Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide.

Authors:  Max Jan; Adam S Sperling; Benjamin L Ebert
Journal:  Nat Rev Clin Oncol       Date:  2021-03-02       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.